Cell- and animal-based models of bone formation reveal novel mechanisms involved in the cartilage-to-bone phenotype ...
A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...
A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...
BUFFALO, NY- October 15, 2024 – A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on ...
Normal, regulated growth of skeletal bones is a crucial part of the growth of mammals. This is a complex process involving the growth of cartilaginous cells or chondrocytes, their transformation into ...
Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva
As flare-ups often precede the formation of new lesions, we are encouraged that this investigational drug may help prevent the progression of FOP. "The loss of mobility created by the abnormal bone ...
Researchers have shown that a naturally occurring peptide (small protein) holds promise as a new therapeutic for osteoporosis and other disorders that feature bone loss, with distinct advantages over ...
A new small molecule could treat and prevent excess bone formation. Fibrodysplasia ossificans progressiva (FOP) is an extremely rare disease estimated to affect about one in 2 million people worldwide ...
Studies by University of Birmingham researchers suggest that a naturally occurring peptide known as PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration), could represent a promising potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results